# Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent

Study · id `cardio:ct-nct01135225` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01135225](<https://clinicaltrials.gov/study/NCT01135225>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT01135225

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.

## Technical summary

Registry record NCT01135225. Randomized; single masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 291 participants (enrolled count; ClinicalTrials.gov record NCT01135225, source copy `cardio:ctgov-nct01135225-2017-02-03`, retrieved 2026-11-18)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01135225, source copy `cardio:ctgov-nct01135225-2017-02-03`, retrieved 2026-11-18)
- Primary completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01135225, source copy `cardio:ctgov-nct01135225-2017-02-03`, retrieved 2026-11-18)
- Completion: 2016-04 (actual) (ClinicalTrials.gov record NCT01135225, source copy `cardio:ctgov-nct01135225-2017-02-03`, retrieved 2026-11-18)
- Countries: Australia; Belgium; Denmark; France; New Zealand; Poland; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01135225, source copy `cardio:ctgov-nct01135225-2017-02-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01135225-2017-02-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
- Acronym: Evolve
- Condition: Coronary Artery Disease
- Intervention (Device): PROMUS(TM) Element (TM) Stent System
- Intervention (Device): Evolution Stent System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent (`cardio:pubmed-22341736`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent (`cardio:pubmed-23872647`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 242a5c721615f7cce1d687d4ba0eb93914a1dbe5c1a50027bb96fc986ae28b0e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
